To overcome these key limitations, we developed AAV9-REGABA-eTFSCN1A, a novel gene regulation therapy, to selectively drive upregulation of endogenous WT SCN1A in GABAergic inhibitory interneurons to rescue haploinsufficiency of SCN1A in DS (Fig. 6). The gene discussed is SCN1A; the disease is Dravet syndrome.